

Press Release

Nicox: Half-year liquidity contract statement for NICOX

January 6, 2022 – release at 7:30 am CET
Sophia Antipolis, France

Under the liquidity contract entered into between Nicox SA (Euronext Paris: FR0013018124, COX) and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:

- 211,967 shares
- € 146,491.49

- Number of executions on buy side on semester: 786
- Number of executions on sell side on semester: 728
- Traded volume on buy side on semester: 387,737 shares for € 1,278,136.61
- Traded volume on sell side on semester: 394,689 shares for € 1,304,467.12

As a reminder :

- the following resources appeared on the last half year statement on 30 June 2021 on the liquidity account:
 - 218,919 shares
 - € 128,032.29

 - Number of executions on buy side on semester: 1,594
 - Number of executions on sell side on semester: 1,298
 - Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01
 - Traded volume on sell side on semester: 906,908 shares for € 3,977,929.37

- the following resources appeared on the liquidity account when the activity started:
 - 0 shares
 - € 500,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	738	337,737	1,273,138.81	728	384,889	1,304,487.12
01/07/2021	-	-	-	5	4,000	14,680.00
02/07/2021	-	-	-	24	14,000	52,780.00
05/07/2021	3	2,000	7,680.00	17	11,435	44,024.75
06/07/2021	8	8,100	30,861.00	-	-	-
07/07/2021	15	12,925	48,339.50	-	-	-
08/07/2021	29	14,075	50,951.50	-	-	-
09/07/2021	1	153	541.62	15	20,000	72,200.00
12/07/2021	14	10,990	39,454.10	1	1	3.65
13/07/2021	8	4,857	17,290.92	-	-	-
14/07/2021	5	3,000	10,530.00	-	-	-
15/07/2021	12	4,737	16,390.02	-	-	-
16/07/2021	6	1,663	5,704.09	1	1	3.47
19/07/2021	14	5,600	18,984.00	-	-	-
20/07/2021	2	1,000	3,330.00	9	8,000	26,880.00
21/07/2021	2	2,000	6,700.00	8	4,000	13,520.00
22/07/2021	4	2,000	6,680.00	18	6,000	20,340.00
23/07/2021	10	3,500	11,410.00	8	4,000	13,320.00
26/07/2021	15	4,764	15,006.60	1	500	1,585.00
27/07/2021	4	836	2,558.16	-	-	-
28/07/2021	1	400	1,264.00	16	6,500	20,735.00
29/07/2021	4	1,200	3,828.00	5	1,000	3,260.00
30/07/2021	6	2,000	6,380.00	14	7,500	24,225.00
02/08/2021	12	3,200	10,336.00	6	2,500	8,200.00
03/08/2021	2	400	1,264.00	2	78	252.72
04/08/2021	3	800	2,512.00	3	327	1,036.59
05/08/2021	3	1,200	3,732.00	4	1,000	3,150.00
06/08/2021	2	2	6.30	8	998	3,193.60
09/08/2021	1	400	1,272.00	10	2,355	7,630.20
10/08/2021	-	-	-	17	5,468	17,716.32
11/08/2021	-	-	-	17	9,974	33,113.68
12/08/2021	14	5,520	18,216.00	6	2,000	6,740.00
13/08/2021	4	2,229	7,244.25	2	2,000	6,580.00
16/08/2021	6	1,771	5,720.33	-	-	-
17/08/2021	9	3,899	12,476.80	-	-	-
18/08/2021	7	1,000	3,210.00	17	6,625	21,597.50
19/08/2021	16	7,000	22,330.00	-	-	-
20/08/2021	3	1,500	4,740.00	1	1	3.22
23/08/2021	-	-	-	11	5,374	17,411.76
24/08/2021	-	-	-	9	6,000	19,740.00
25/08/2021	-	-	-	6	2,000	6,600.00
26/08/2021	1	68	221.00	3	2,000	6,660.00
27/08/2021	3	2,000	6,540.00	1	2,000	6,620.00
30/08/2021	-	-	-	17	7,468	25,391.20
31/08/2021	1	2,000	7,060.00	41	16,531	58,519.74
01/09/2021	-	-	-	24	16,362	59,994.72
02/09/2021	2	2,200	8,008.00	6	3,607	13,418.04
03/09/2021	3	2,180	8,218.60	41	14,607	55,360.53
06/09/2021	14	7,820	29,325.00	3	935	3,581.05
07/09/2021	4	1,263	4,698.36	2	603	2,267.28
08/09/2021	17	9,919	36,799.49	-	-	-
09/09/2021	13	4,583	16,773.78	23	18,000	67,860.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume In EUR	Number of executions	Number of shares	Traded volume In EUR
Total	786	387,737	1,278,136.61	728	394,689	1,304,467.12
10/09/2021	19	8,000	30,160.00	-	-	-
13/09/2021	28	21,035	76,148.70	-	-	-
14/09/2021	6	4,001	14,243.56	-	-	-
15/09/2021	1	310	1,097.40	5	4,000	14,320.00
16/09/2021	10	2,000	7,180.00	3	2,000	7,240.00
17/09/2021	1	1,690	5,982.60	-	-	-
20/09/2021	8	6,000	20,940.00	-	-	-
21/09/2021	10	6,370	22,040.20	1	1	3.53
22/09/2021	1	1	3.43	7	3,999	14,076.48
23/09/2021	34	20,630	68,697.90	-	-	-
24/09/2021	16	7,505	24,241.15	-	-	-
27/09/2021	11	3,399	10,842.81	3	2,000	6,480.00
28/09/2021	1	147	468.93	-	-	-
29/09/2021	1	2,000	6,380.00	4	4,000	12,880.00
30/09/2021	8	4,000	12,680.00	4	1,171	3,747.20
01/10/2021	-	-	-	2	848	2,713.60
04/10/2021	3	4,000	12,640.00	5	2,000	6,400.00
05/10/2021	1	1,000	3,170.00	5	6,000	19,500.00
06/10/2021	12	5,405	17,025.75	-	-	-
07/10/2021	8	1,995	6,264.30	2	2,000	6,320.00
08/10/2021	8	4,000	12,720.00	4	4,000	12,720.00
11/10/2021	5	2,000	6,260.00	2	301	966.21
12/10/2021	-	-	-	15	7,699	24,867.77
13/10/2021	2	3,000	9,660.00	-	-	-
14/10/2021	-	-	-	12	6,000	19,740.00
15/10/2021	-	-	-	11	6,000	19,920.00
18/10/2021	1	39	130.26	5	6,000	20,520.00
19/10/2021	5	2,500	8,325.00	1	3	10.08
20/10/2021	-	-	-	7	3,997	13,469.89
21/10/2021	10	7,000	23,380.00	1	2,000	6,760.00
22/10/2021	2	1,000	3,340.00	1	2,000	6,800.00
25/10/2021	10	8,000	26,320.00	-	-	-
26/10/2021	11	4,000	12,880.00	-	-	-
27/10/2021	4	1,965	6,252.75	1	218	704.14
28/10/2021	1	15	47.10	-	-	-
29/10/2021	-	-	-	18	7,962	25,861.68
01/11/2021	1	1	3.24	2	2,000	6,600.00
02/11/2021	5	2,316	7,619.64	-	-	-
03/11/2021	4	3,000	9,810.00	6	3,500	11,620.00
04/11/2021	9	3,999	12,916.77	-	-	-
05/11/2021	16	4,800	15,312.00	-	-	-
08/11/2021	7	1,701	5,375.16	-	-	-
09/11/2021	2	45	142.65	7	5,000	16,000.00
10/11/2021	5	2,000	6,380.00	2	185	597.55
11/11/2021	5	2,000	6,420.00	-	-	-
12/11/2021	4	2,000	6,400.00	5	3,815	12,284.30
15/11/2021	11	4,954	15,753.72	6	1,344	4,327.68
16/11/2021	8	1,078	3,428.04	-	-	-
17/11/2021	5	1,000	3,170.00	6	2,907	9,418.68
18/11/2021	7	3,000	9,420.00	4	2,000	6,320.00
19/11/2021	5	2,000	6,260.00	-	-	-

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	786	387,737	1,278,136.61	728	354,689	1,304,467.12
22/11/2021	13	4,025	12,477.50	-	-	-
23/11/2021	6	2,175	6,855.50	1	842	2,610.20
24/11/2021	5	700	2,135.00	1	1	3.08
25/11/2021	2	1,000	3,060.00	4	1,499	4,616.92
26/11/2021	19	6,400	19,072.00	-	-	-
29/11/2021	2	1,000	2,910.00	10	5,485	16,125.90
30/11/2021	5	3,000	8,780.00	1	1,000	2,980.00
01/12/2021	-	-	-	23	9,350	28,424.00
02/12/2021	-	-	-	6	2,561	7,836.66
03/12/2021	12	3,823	11,469.00	-	-	-
06/12/2021	10	5,177	15,272.15	-	-	-
07/12/2021	-	-	-	3	1,000	2,950.00
08/12/2021	-	-	-	2	4,000	11,720.00
09/12/2021	16	9,500	26,885.00	3	1,001	2,972.97
10/12/2021	7	3,200	8,768.00	-	-	-
13/12/2021	6	3,000	8,040.00	3	2,000	5,520.00
14/12/2021	3	2,000	5,220.00	-	-	-
15/12/2021	4	3,000	7,710.00	-	-	-
16/12/2021	-	-	-	20	18,200	48,048.00
17/12/2021	1	1,100	2,860.00	26	16,000	42,560.00
20/12/2021	8	4,901	12,791.61	7	2,000	5,400.00
21/12/2021	7	5,999	15,537.41	-	-	-
22/12/2021	2	562	1,449.96	10	3,186	8,315.46
23/12/2021	3	3,000	7,740.00	7	4,814	12,660.82
24/12/2021	-	-	-	6	2,000	5,180.00
27/12/2021	2	1,000	2,800.00	3	2,000	5,240.00
28/12/2021	11	6,000	15,360.00	1	2,000	5,160.00
29/12/2021	4	2,000	5,060.00	2	1,215	3,134.70
30/12/2021	3	1,500	3,765.00	5	1,500	3,795.00
31/12/2021	-	-	-	5	2,285	5,849.60

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIA® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Dylan van Haften	Paris, France
Edison Investment Research	Pooya Hemami	London, UK
H.C. Wainwright & Co	Yi Chen	New York, U.S.
Kepler Cheuvreux	Damien Choplain	Paris, France



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox

Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media

United States & Europe
LifeSci Advisors, LLC
Sandy von der Weid
T +41 78 680 05 38
svonderweid@lifesciadvisors.com

Media

France
LifeSci Advisors, LLC
Sophie Baumont
T +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the '*Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2020*' filed with the French *Autorité des Marchés Financiers* (AMF) on March 1, 2021 and in the 2nd chapter of the amendment to the '*Document d'Enregistrement Universel, rapport financier annuel et rapport de gestion 2020*' filed with the AMF on December 9, 2021 which are available on Nicox's website (www.nicox.com).

Nicox S.A.

Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99